ArticlePediatric cardiology2026
Long-Term Fate of the Systemic Right Ventricle: In Patients with Bi-ventricle Versus Single Ventricle.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unique anatomical and physiological characteristics of the systemic right ventricle (sRV) raise prognostic concerns. This study aimed to characterize its long-term clinical course and identify risk factors for adverse outcomes. Patients with sRV who underwent biventricle (BiV) repair or Fontan procedure between January 2000 and July 2023 were reviewed. Comparative analysis between patients with BiV status and single ventricle (SV), and risk factor analysis were performed for long-term outcomes including overall survival and adverse outcomes. In total, 141 patients with sRV (median age 3.1 years (interquartile range (IQR) 2.5-3.8), male 63.1%) were enrolled, with 117 patients (83.0%) undergoing Fontan procedure and 24 patients (17.0%) undergoing BiV repair. Median follow-up duration was 14.3 years (IQR 5.9-18.5). There were no significant differences between BiV and SV in overall survival, composite endpoint for heart failure, percutaneous intervention and major arrhythmia events. BiV showed significantly higher cumulative incidence of re-operation (5-, 10-, 15-year cumulative incidence: 0.340, 0.449, 0.449 vs. 0.136, 0.178, 0.178, p = 0.011) and tricuspid valve surgery (5-, 10-, 15-year cumulative incidence: 0.217, 0.402, 0.402 vs. 0.009, 0.031, 0.031, 0.031, p < 0.001). Multivariable risk factor analysis identified BiV as a significant risk factor for re-operation (subdistribution hazards ratio (sHR) 2.759, 95% confidence interval (CI) 1.028-7.407, p = 0.044) and tricuspid valve surgery (sHR 13.709, 95% CI 1.176-166.667, p = 0.037). sRV, both in SV or BiV circulation, showed good adaptability and tolerable early long-term performance. The follow-up of patients with a sRV requires careful consideration of disease-specific differences and the adoption of individualized surveillance strategies for each condition.
Indexed as
Identifiers
42423983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.